LEI:
549300Q7EXQQH6KF7Z84
14 March
2024
RTW Biotech Opportunities
Ltd
Monthly Valuation Update &
Factsheet
RTW Biotech Opportunities Ltd (the
"Company" or "RTW Bio") announces that the unaudited
net asset value attributable to the ordinary shares of the Company
(the "NAV") at the close of
business on 29 February was US$658.3m, or US$1.93 per ordinary
share.
The monthly factsheet
is available on the Company's website:
https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/factsheets-letters/
It is important to note that the above NAV and
NAV per share are unaudited and are calculated based on the
following assumptions and calculations:
· 341,163,649
shares were used as the denominator for the per share
calculation. As per the "Completion of
Acquisition" announcement published on 13 February 2024, the
calculation of the denominator excludes 48,322,863 New RTW Bio
Shares issued to RTW Biotech Opportunities Operating Ltd in respect
of its shareholding in Arix held by the Company.
· Certain Arix private assets have been valued on a preliminary
basis pending implementation of the Manager's full valuation
process.
· The
return of some additional, reasonably expected excess capital held
by the Arix liquidator.
For
Further Information:
|
RTW
Investments, LP
|
+44
20 7959 6361
|
|
Woody Stileman, Managing Director,
Business Development
Krisha McCune, Director, Investor
Relations
|
ir@rtwfunds.com
|
|
|
|
|
Buchanan (PR & Communications Adviser)
|
+44
20 7466 5107
|
|
Charles Ryland
|
|
|
Henry Wilson
|
|
|
George Beale
|
|
|
|
|
|
Deutsche Numis (Joint Corporate Broker)
|
+44
20 7260 1000
|
|
Freddie Barnfield
|
|
|
Nathan Brown
|
|
|
Euan Brown
|
|
|
|
|
|
BofA Securities (Joint Corporate Broker)
|
+44
20 7628 1000
|
|
Edward Peel
|
|
|
Alex Penney
|
|
|
Cadarn Capital (Distribution & IR
Partner)
|
+44
73 6888 3211
|
|
David Harris
|
|
|
Elysium Fund Management Limited
Joanna Duquemin Nicolle, Chief
Executive Officer
Sadie Morrison, Managing
Director
|
+44
(0) 14 8181 0100
|
|
Morgan Stanley Fund Services USA LLC
|
+1
914 225 8885
|
About Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE:
RTW & RTWG) is an investment fund focused on identifying
transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a
long-term approach to support innovative businesses, RTW Biotech
Opportunities Ltd invests in companies developing next-generation
therapies and technologies that can significantly improve patients'
lives. RTW Biotech Opportunities Ltd is managed by RTW Investments,
LP, a leading healthcare-focused
entrepreneurial investment firm with
deep scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the website
at www.rtwfunds.com/rtw-biotech-opportunities-ltd for
more information.